Race Oncology June 2022 Quarterly Investor Briefing

Race Oncology June 2022 Quarterly Investor Briefing
28 Jul
Jul , 28 , 2022 Daniel Tillett

Race Oncology CEO Phillip Lynch and CSO Dr Daniel Tillett present Race’s June 2022 Quarterly Investor Briefing followed by a Q&A session.

LinkedIn

Related posts:

Zantrene Protects Mouse Hearts from Chemotherapy Damage Race Receives Human Ethics Approval for Extramedullary AML & MDS Trial Race appoints Dr David Fuller Chief Medical Officer